New hope for men with Fast-Moving prostate cancer
NCT ID NCT07179783
Summary
This study is testing whether a combination of two drugs—an antibody-drug conjugate and an immunotherapy drug—can help control aggressive forms of prostate cancer that have stopped responding to standard hormone therapies. It will enroll 28 men in China with advanced, fast-growing prostate cancer to see if the treatment shrinks tumors and is safe. The goal is to find a better option for these difficult-to-treat cancers, which currently have very limited treatment choices and poor survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER (ADENOCARCINOMA) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical Unversity Second Hospital
RECRUITINGTianjin, Tianjin Municipality, 300211, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.